RettBASE: Rett syndrome database update

Rett syndrome (RTT) is an X‐linked progressive neurodevelopmental disorder that primarily affects females. Mutations in the MECP2 gene have been attributed as the major genetic cause of RTT. Recently, mutations in CDKL5 and FOXG1 genes have also been suggested to give rise to RTT, although subsequent more extensive studies suggest that diseases resulting from mutations in these two genes should be considered as distinct clinical entities. While the genetic basis for the RTT has been recognized, so far there is no effective cure for the disease and the treatments available are mainly aimed at ameliorating clinical problems associated with the disorder. The swift identification of the mutations in children is crucial for pursuing the best therapeutic care. RettBASE was created in 2002 as a MECP2 variant database and has grown to become a comprehensive variant database for RTT and related clinical phenotypes, containing a curated collection of variants for MECP2, CDKL5, and FOXG1 genes. Here, we describe the development and growth of RettBASE after its inception in 2001. Currently, RettBASE holds a total of 4,668 variants in MECP2, 498 variants in CDKL5, and 64 variants in FOXG1.

[1]  N. Laing,et al.  Effects of MECP2 mutation type, location and X‐inactivation in modulating Rett syndrome phenotype , 2003, American journal of medical genetics. Part A.

[2]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[3]  K. Yamakawa,et al.  Mutational analysis of the MECP2 gene in Japanese patients with Rett syndrome , 2000, Journal of Human Genetics.

[4]  A. Renieri,et al.  Seizures and electroencephalographic findings in CDKL5 mutations: Case report and review , 2007, Brain and Development.

[5]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[6]  J. Armstrong,et al.  Novel FOXG1 mutations associated with the congenital variant of Rett syndrome , 2009, Journal of Medical Genetics.

[7]  D. Horn,et al.  The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis , 2011, Journal of Medical Genetics.

[8]  Hye-Seung Lee,et al.  Developmental delay in Rett syndrome: data from the natural history study , 2014, Journal of Neurodevelopmental Disorders.

[9]  F. Volkmar,et al.  Brief Report: Systematic Review of Rett Syndrome in Males , 2015, Journal of autism and developmental disorders.

[10]  S. Scherer,et al.  A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome , 2004, Nature Genetics.

[11]  A. Bird,et al.  Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. , 1992, Nucleic acids research.

[12]  Stephen T. C. Wong,et al.  MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription , 2008, Science.

[13]  W. Kaufmann,et al.  Rett syndrome: Revised diagnostic criteria and nomenclature , 2010, Annals of neurology.

[14]  E. Cook,et al.  Novel de novo nonsense mutation of MECP2 in a patient with Rett syndrome , 2000, Human mutation.

[15]  J. Gécz,et al.  Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. , 2004, American journal of human genetics.

[16]  Y. Egashira,et al.  miR-199a Links MeCP2 with mTOR Signaling and Its Dysregulation Leads to Rett Syndrome Phenotypes. , 2015, Cell reports.

[17]  E. Monrós,et al.  Classic rett syndrome in a boy as a result of somatic mosaicism for a mecp2 mutation , 2001, Annals of neurology.

[18]  Andrew J. Grimm,et al.  RettBASE: The IRSA MECP2 variation database—a new mutation database in evolution , 2003, Human mutation.

[19]  W. Kaufmann,et al.  Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome , 2014, Journal of Medical Genetics.

[20]  J. Raber,et al.  A role for glia in the progression of Rett’s syndrome , 2011, Nature.

[21]  Johan T den Dunnen,et al.  Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker , 2008, Human mutation.

[22]  J. Christodoulou,et al.  Rett syndrome: clinical characteristics and recent genetic advances , 2001, Disability and rehabilitation.

[23]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[24]  F. Pidcock,et al.  Functional outcomes in Rett syndrome , 2016, Brain and Development.

[25]  M. Nakao,et al.  Functional analyses of MeCP2 mutations associated with Rett syndrome using transient expression systems , 2001, Brain and Development.

[26]  N. Landsberger,et al.  CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. , 2005, Human molecular genetics.

[27]  T. Charman,et al.  Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation , 2006, Journal of Medical Genetics.

[28]  E. Gaily,et al.  Epilepsy caused by CDKL5 mutations. , 2011, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[29]  G. Mandel,et al.  Oligodendrocyte Lineage Cells Contribute Unique Features to Rett Syndrome Neuropathology , 2013, The Journal of Neuroscience.

[30]  Carol Bower,et al.  Rett syndrome in Australia: a review of the epidemiology. , 2006, The Journal of pediatrics.

[31]  L. Wilkins.  The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome , 2009, Neurology.

[32]  E. Kanavakis,et al.  A novel p.Arg970X mutation in the last exon of the CDKL5 gene resulting in late-onset seizure disorder. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[33]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[34]  A. Bisgaard,et al.  Is it possible to diagnose Rett syndrome before classical symptoms become obvious? Review of 24 Danish cases born between 2003 and 2012. , 2015, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[35]  H. Zoghbi,et al.  Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome , 2008, Neurology.

[36]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[37]  P. Avner,et al.  Random X-chromosome inactivation: skewing lessons for mice and men. , 2006, Current opinion in genetics & development.

[38]  G. Mandel,et al.  Non–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology , 2009, Nature Neuroscience.

[39]  M. Zatz,et al.  Rett syndrome in a boy with a 47,XXY karyotype confirmed by a rare mutation in the MECP2 gene. , 2001, Neuropediatrics.

[40]  T. Charman,et al.  Correlation between clinical severity in patients with Rett syndrome with a p . R 168 X or p . T 158 M MECP 2 mutation , and the direction and degree of skewing of X-chromosome inactivation , 2007 .

[41]  Meredith Wilson,et al.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy , 2012, European Journal of Human Genetics.